Erin Wright
Stock Analyst at Morgan Stanley
(4.51)
# 264
Out of 4,751 analysts
218
Total ratings
64.56%
Success rate
13.64%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintains: Equal-Weight | $14 → $13 | $10.93 | +18.99% | 11 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $243 → $238 | $164.98 | +44.26% | 7 | Feb 14, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $301 → $285 | $261.44 | +9.01% | 3 | Feb 12, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $19 → $20 | $19.85 | +0.76% | 7 | Feb 6, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $280 → $272 | $185.77 | +46.42% | 21 | Feb 6, 2025 | |
| CI The Cigna Group | Maintains: Overweight | $403 → $379 | $302.92 | +25.12% | 4 | Jan 31, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $136 → $142 | $127.47 | +11.40% | 9 | Jan 31, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $559 → $550 | $441.03 | +24.71% | 12 | Jan 29, 2025 | |
| PDCO Patterson Companies | Maintains: Equal-Weight | $27 → $31 | $31.15 | +0.64% | 9 | Dec 17, 2024 | |
| MCK McKesson | Maintains: Overweight | $612 → $642 | $620.85 | +3.41% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $25 | $22.14 | +12.92% | 21 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $17.15 | +34.11% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $19.23 | +4.00% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $171.55 | +0.26% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $643 → $551 | $392.87 | +40.25% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $9 → $7 | $11.23 | -37.67% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $6.5 → $3.5 | $4.32 | -18.89% | 11 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $72.11 | -9.86% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $64.48 | +55.09% | 4 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $468.56 | +25.28% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $247.79 | +21.07% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $16.49 | +154.70% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $205.71 | +40.00% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $164.88 | +113.49% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $3.05 | +1,342.62% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $326.11 | -44.50% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $91.49 | -81.42% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $36.13 | +234.90% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $523.23 | +10.85% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $12.40 | +182.26% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $189.63 | +8.11% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $15.90 | -30.82% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $186.50 | -15.82% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $18.03 | +110.76% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $6.89 | +146.73% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $446.46 | -31.01% | 1 | Oct 25, 2017 |
Elanco Animal Health
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $10.93
Upside: +18.99%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $164.98
Upside: +44.26%
Humana
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $301 → $285
Current: $261.44
Upside: +9.01%
Envista Holdings
Feb 6, 2025
Maintains: Equal-Weight
Price Target: $19 → $20
Current: $19.85
Upside: +0.76%
Align Technology
Feb 6, 2025
Maintains: Overweight
Price Target: $280 → $272
Current: $185.77
Upside: +46.42%
The Cigna Group
Jan 31, 2025
Maintains: Overweight
Price Target: $403 → $379
Current: $302.92
Upside: +25.12%
Cardinal Health
Jan 31, 2025
Maintains: Overweight
Price Target: $136 → $142
Current: $127.47
Upside: +11.40%
IDEXX Laboratories
Jan 29, 2025
Maintains: Overweight
Price Target: $559 → $550
Current: $441.03
Upside: +24.71%
Patterson Companies
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $27 → $31
Current: $31.15
Upside: +0.64%
McKesson
Dec 17, 2024
Maintains: Overweight
Price Target: $612 → $642
Current: $620.85
Upside: +3.41%
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $22.14
Upside: +12.92%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $17.15
Upside: +34.11%
Dec 17, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $19.23
Upside: +4.00%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $171.55
Upside: +0.26%
Oct 23, 2024
Maintains: Overweight
Price Target: $643 → $551
Current: $392.87
Upside: +40.25%
Oct 11, 2024
Maintains: Underweight
Price Target: $9 → $7
Current: $11.23
Upside: -37.67%
Jun 12, 2024
Maintains: Underweight
Price Target: $6.5 → $3.5
Current: $4.32
Upside: -18.89%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $72.11
Upside: -9.86%
Nov 2, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $64.48
Upside: +55.09%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $468.56
Upside: +25.28%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $247.79
Upside: +21.07%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $16.49
Upside: +154.70%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $205.71
Upside: +40.00%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $164.88
Upside: +113.49%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $3.05
Upside: +1,342.62%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $326.11
Upside: -44.50%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $91.49
Upside: -81.42%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $36.13
Upside: +234.90%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $523.23
Upside: +10.85%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $12.40
Upside: +182.26%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $189.63
Upside: +8.11%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $15.90
Upside: -30.82%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $186.50
Upside: -15.82%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $18.03
Upside: +110.76%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $6.89
Upside: +146.73%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $446.46
Upside: -31.01%